Inhospital Mortality in Patients with Type 2 Diabetes Mellitus: A Prospective Cohort Study in Lima, Peru

Henry Zelada,1,2,3 Antonio Bernabe-Ortiz,2,4,5 and Helard Manrique6

1 Internal Medicine Training Program, Louis A. Weiss Memorial Hospital, 4646 N. Marine Drive, Chicago, IL 60640, USA
2 School of Public Health and Administration, Peruvian University Cayetano Heredia, Lima, Peru
3 School of Medicine, Peruvian University Cayetano Heredia, Lima, Peru
4 Center of Excellence in Chronic Diseases (CRONICAS), Peruvian University Cayetano Heredia, Lima, Peru
5 School of Medicine, Peruvian University of Applied Sciences, Lima, Peru
6 Arzobispo Loayza National Hospital, Lima, Peru

Correspondence should be addressed to Henry Zelada; hzeladac@weisshospital.com

Received 22 May 2015; Accepted 16 August 2015

Objective. To estimate cause of death and to identify factors associated with risk of inhospital mortality among patients with T2D.

Methods. Prospective cohort study performed in a referral public hospital in Lima, Peru. The outcome was time until event, elapsed from hospital admission to discharge or death, and the exposure was the cause of hospital admission. Cox regression was used to evaluate associations of interest reporting Hazard Ratios (HR) and 95% confidence intervals.

Results. 499 patients were enrolled. Main causes of death were exacerbation of chronic renal failure (38.1%), respiratory infections (35.7%), and stroke (16.7%). During hospital stay, 42 (8.4%) patients died. In multivariable models, respiratory infections (HR = 6.55, 𝑝< 0.001), stroke (HR = 7.05, 𝑝 = 0.003), and acute renal failure (HR = 16.9, 𝑝 = 0.001) increased the risk of death. In addition, having 2+ (HR = 7.75, 𝑝< 0.001) and 3+ (HR = 21.1, 𝑝< 0.001) conditions increased the risk of dying.

Conclusion. Respiratory infections, stroke, and acute renal disease increased the risk of inhospital mortality among hospitalized patients with T2D. Infections are not the only cause of inhospital mortality. Certain causes of hospitalization require standardized and aggressive management to decrease mortality.

1. Introduction

Worldwide, an estimated 382 million people live with type 2 diabetes (T2D), causing at least US 548 billion dollars in health care expenditures [1], and 80% of these people were living in low- and middle-income countries (LMIC) [2]. Besides, approximately 5.1 million individuals die because of T2D and nearly half of these deaths occur in people under the age of 60 [1].

There is scarce information regarding mortality rates and causes of death in patients with T2D in LMIC. For many years, infections have been considered the main cause of mortality in LMIC, despite the fact that vascular diseases, especially stroke and myocardial infarction, are the underlying causes in high-income countries [3, 4]. Due to the relatively fast nutritional and epidemiological transition LMIC are going through, it is necessary to determine potential causes of death among T2D patients in resource-constrained settings to implement appropriate strategies.

Information regarding inhospital mortality rates as well as clinical conditions increasing the risk of dying among T2D patients is very limited in resource-constrained settings. As a result, there is a lack of preventive policies in high-risk T2D cases that might reduce and prevent inhospital mortality. For example, a previous study, conducted in Peru in 1996, reported that infections were the main cause of morbidity and mortality in a public referral hospital [5]; however, current circumstances might have changed.

As a result, the aim of this study was to identify potential clinical factors that might increase the risk of inhospital mortality among T2D patients. In addition, mortality rate and main causes of hospital admission and death were also determined. Results of this study can be helpful to implement public health strategies and update hospital management.
Table 1: Definition of causes of hospitalization assessed in the study.

| Causes                        | Definition                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|
| Infections                    |                                                                             |
| Respiratory                   | Respiratory symptoms (cough or tachypnea) plus a chest X-ray with changes suggestive of viral or bacterial respiratory infection. |
| Urinary                       | Urine sample with ≥10 leukocytes/μL [30], temperature > 38.0°C, and not being able to orally tolerate fluids/food. |
| Gastrointestinal              | Diarrhea < 7 days, vomiting, and dehydration.                              |
| Subcutaneous tissue (SCT)     | Cellulitis or necrotizing fasciitis in any part of the body except feet.   |
| Diabetic foot                 | Ulceration, infection, and/or gangrene of foot associated with diabetic neuropathy and different grades of peripheral artery disease [21]. |
| Metabolic disorders           |                                                                             |
| Hypoglycemia                  | Glucose ≤70 mg/dL (3.9 mmol/L) [21].                                       |
| Diabetic ketoacidosis         | Glucose >250 mg/dL, pH <7.3, and bicarbonate <18 mEq/d [21].               |
| Hyperosmolar state            | Glucose >600 mg/dL, pH arterial: >7.30, bicarbonate: >18 mEq/L, anion GAP: variable, mental status: drowsy/coma, few kenotic bodies in the urine and blood, and plasmatic osmolality > 320 mOsm/kg [21]. |
| Vascular                      |                                                                             |
| Stroke                        | Fast development of clinic signs of changes in the cerebral function or global, with symptoms that persist within 24 hours or more, with no other evidence of vascular origin [21]. |
| Renal                         |                                                                             |
| Acute renal failure           | Sudden increase (within 48 hours) of creatinine (Cr) ≥0.3 mg/dL (26.4 micromol/L) of basal or a percentage of increment of Cr of ≥50%; or oliguria of <0.5 mL/kg/hour by more than six hours [31]. |
| Chronic renal failure         | Presence of renal damage (urinary albumin excretion ≥30 mg/day) or decrease of the renal function (GFR <60 mL/min/1.73 m²) by three or more months, independent of the cause [32] documented as past medical history plus acute renal failure at the moment of admission (exacerbation). |

The exposure of interest was the cause of hospitalization defined as the diagnosis at the moment of hospital admission. Only one physician, one of the authors of this paper, was responsible for verifying and confirming the cause of hospitalization during follow-up. Causes of hospitalization were subdivided into the most common reasons previously reported including infections (urinary, respiratory, subcutaneous tissue, or diabetic foot), metabolic disorders (hypoglycemia, diabetic ketoacidosis, and hyperosmolar state), stroke, and acute and chronic renal failure (exacerbation). Definitions of the variables used are detailed in Table 1. In addition, causes of hospitalization were also grouped by addition and then assessed as an independent exposure as T2D patients might present different morbidities at the same time.

Clinical variables, especially related to T2D, were also considered including time of disease, in years, split in four categories (<5, 5–9, 10–14, and 15+), type of hospital admission (outpatient service or emergency), and medicines received prior to hospital admission (yes/no). Besides, glycated hemoglobin (HbA1c) level was categorized as non-controlled (≥7%) and controlled (<7%), according to international guidelines [7]. Finally, sociodemographic variables were also evaluated as potential confounders, including gender, age in years (<50, 50–59, 60–69, or ≥70), region of birth (coast, highlands, or jungle), and education level (<7 years, 7–11 years, or ≥12 years).

2. Methods

2.1. Study Design and Setting. A prospective cohort study was conducted in the Internal Medicine Hospitalization Unit at the Hospital Nacional Arzobispo Loayza (HNAL) located in Lima, Peru. HNAL is a third-level public hospital located in the center of Lima, with more than 2500 hospital admissions monthly in the different available services and more than 30,000 outpatients attending every month [6].

2.2. Selection of Participants. Patients with T2D diagnosis, confirmed by an internal medicine physician or endocrinologist in the emergency or ambulatory room, aged 18 or more and admitted to the Internal Medicine Service of the HNAL during the year 2012 were enrolled in the study. In case of multiple hospitalizations during the year, only the first hospital admission was included in the analyses. Pregnant women and patients admitted for diagnostic or therapeutic procedures such as kidney biopsy, peritoneal dialysis catheter placement, or corticosteroid pulse were excluded.

2.3. Variables Definition. The outcome of interest was time until event defined as the time, in days, elapsed from admission until the patient was discharged by medical indication or voluntary decision (censored) or died during hospitalization.

2.4. Procedures. Previous informed consent, third-year residents of Endocrinology evaluated the patients that fulfill the inclusion criteria for the study. Residents were trained before
starting fieldwork activities to appropriately applied questionnaires and complete data collection templates. Sociodemographic, clinical, and laboratory data was recorded at the moment of hospital admission. Patients were then followed up for diagnosis confirmation as well as recording the outcome of interest (discharge or death).

2.5. Sample Size and Power. Using Power and Sample Size software (PASS 2008, NCSS, UTAH, US), with information from 499 participants and assuming a level of significance of 5% and a mortality rate of 0.57 per 100 persons-day of follow-up, we have a power of 80% to detect a Hazard Ratio of 3 or more.

2.6. Data Analysis. STATA 13 for Windows (STATA Corporation, College Station, Texas, US) was used for statistical analysis. Initially, the study population was described using mean and standard deviation for numerical variables and proportions for categorical variables. Association between inhospital mortality rate and sociodemographic, clinical variables and causes of hospitalization were assessed using Log-rank test. After that, Cox regression crude and adjusted models were fitted to evaluate associations between causes of hospitalization (individual and grouped) and our outcome of interest, reporting Hazard Ratios (HR) and their respective 95% confidence intervals (95% CI).

Because a large proportion of patients (40.2%) did not have HbA1c results and 11.8% did not have time of disease information, with both considered important confounders in the models, the associations of interest were also evaluated using multiple imputation techniques, based on data collected. As recommended in previous studies [8–10] and because of being feasible, 20 imputations were made to reduce sample errors. Despite not being considered a good practice [11], association was also evaluated using Cox regression models with an extra “missing value” category in HbA1c and time of disease variables.

2.7. Ethics. The study was reviewed and approved by the Institutional Ethical Committee of Universidad Peruana Cayetano Heredia, Lima, Peru. Oral informed consent was requested from participants before fieldwork activities. Data collection templates contained alphanumeric codes to avoid personal identifiers.

3. Results

3.1. Characteristics of the Study Population. A total of 499 patients were enrolled during the study, 63.6% female, mean age 61.6 (SD: 13.8) years. Of note, 33.6% of patients reported 15 or more years of disease, only 343 (68.6%) were receiving treatment before hospitalization (20.5% with insulin and 62.4% with metformin), and only 71/299 (23.8%) met recommended glycemic goals (HbA1c < 7%). Among infections, the main causes of hospital admission were urinary infections (23.0%), followed by diabetic foot (22.4%). Among noncommunicable diseases, the main cause of hospitalization was exacerbation of chronic renal failure (18.8%) and stroke (5.6%). Of note, only 4 cases (0.8%) were admitted with diagnosis of acute myocardial infarction.

3.2. Death during Hospitalization and Causes. During the study, 42 (8.4%) patients died with a median survival time of 7 days (interquartile range: 2–17). Detailed characteristics of the study population according to the outcome of interest are shown in Table 2. Overall mortality rate per 100 persons-day of follow-up was 0.57 (95% CI: 0.42–0.78) and varied from 0.21 among those with diabetic foot to 10.7 among those with acute renal disease (Table 3). None of the demographic and T2D-related variables were associated with mortality. The main causes of death were exacerbation of the chronic renal

| Gender | Time to event (mean, in days) | Dead/total (n = 42) | p value* |
|--------|-----------------------------|---------------------|---------|
| Female | 9.9                         | 30/314 (9.5%)       | 0.15    |
| Male   | 17.8                        | 12/180 (6.7%)       |         |
| Age (years) |            |                     |         |
| <50 years | 11.3                    | 3/91 (3.3%)         | 0.12    |
| 50–59 years | 10.6                    | 9/132 (6.8%)        |         |
| 60–69 years | 11.7                    | 14/125 (11.2%)      |         |
| 70+ years | 13.5                    | 16/149 (10.7%)      |         |
| Place of origin |      |                     |         |
| Coast   | 11.8                       | 36/418 (8.6%)       |         |
| Highlands | 13.0                    | 4/60 (6.7%)         | 0.90    |
| Jungle  | 16.0                       | 2/19 (10.5%)        |         |
| Education level |      |                     |         |
| <7 years | 8.6                       | 21/236 (8.9%)       |         |
| 7–11 years | 21.1                    | 13/204 (6.4%)       |         |
| 12+ years | 5.0                       | 5/51 (9.8%)         |         |
| Time of disease (years) |      |                     |         |
| <5 years | 9.8                       | 13/131 (9.9%)       | 0.97    |
| 5–9 years | 17.7                     | 6/77 (7.8%)         |         |
| 10–14 years | 5.0                     | 6/85 (7.1%)         |         |
| 15+ years | 13.7                     | 14/148 (9.5%)       |         |
| Hospital admission |    |                     |         |
| Outpatient | 12.3                    | 39/465 (8.4%)       | 0.73    |
| Emergency | 10.0                     | 3/33 (9.1%)         |         |
| Receiving treatment before admission | |                     |         |
| No     | 10.5                       | 15/156 (9.6%)       | 0.35    |
| Yes    | 13.0                       | 27/343 (7.9%)       |         |
| Glycemic control (HbA1c) |      |                     |         |
| Controlled (<7%) | 11.1                  | 8/71 (11.3%)        | 0.14    |
| Uncontrolled (≥7%) | 10.7                  | 13/228 (5.7%)       |         |

*Log-rank test was used to calculate p values.
Table 3: Factors associated with mortality during hospital admission: crude and adjusted models using Cox regression.

| Condition                  | Dead/total (n = 42) | Mortality Rate (95% CI) | Crude model HR (95% CI) | Adjusted model* HR (95% CI) | Imputed model** HR (95% CI) |
|----------------------------|--------------------|------------------------|-------------------------|-----------------------------|-----------------------------|
| Urinary infection          | No 35/385 (9.1%)   | 0.59 (0.42–0.83)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 7/114 (6.1%)   | 0.48 (0.23–1.01)       | 0.77 (0.34–1.75)        | 1.04 (0.27–3.98)            | 0.70 (0.28–1.72)            |
| Respiratory infection      | No 27/438 (6.2%)   | 0.41 (0.28–0.61)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 15/61 (24.6%)  | 1.68 (1.01–2.78)       | **4.26 (2.25–8.10)**   | **5.65 (2.09–20.50)**       | **5.62 (2.53–12.50)**       |
| Gastrointestinal infection | No 38/461 (8.2%)   | 0.55 (0.40–0.76)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 4/38 (10.5%)   | 0.82 (0.31–2.19)       | 1.49 (0.53–4.19)        | 1.04 (0.12–8.79)            | 1.91 (0.65–5.64)            |
| Subcutaneous infection     | No 36/459 (7.8%)   | 0.53 (0.38–0.74)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 6/39 (15.4%)   | 1.14 (0.51–2.53)       | **2.18 (0.91–5.19)**   | **1.71 (0.33–8.79)**        | **1.36 (0.45–4.09)**        |
| Diabetic foot              | No 36/437 (9.3%)   | 0.73 (0.52–1.02)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 5/111 (4.5%)   | 0.21 (0.09–0.51)       | **0.30 (0.11–0.77)**   | **0.13 (0.02–0.74)**        | **0.28 (0.10–0.76)**        |
| Hypoglycemia               | No 39/449 (8.7%)   | 0.57 (0.41–0.78)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 3/50 (6.0%)    | 0.68 (0.22–2.10)       | 1.07 (0.33–3.50)        | 0.80 (0.09–6.88)            | 0.73 (0.17–3.21)            |
| Diabetic ketoacidosis      | No 40/462 (8.7%)   | 0.58 (0.43–0.80)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 2/36 (5.6%)    | 0.44 (0.11–1.74)       | 0.72 (0.17–2.97)        | 4.77 (0.49–46.71)           | 2.07 (0.46–9.37)            |
| Hyperosmolar state         | No 40/482 (8.3%)   | 0.56 (0.41–0.76)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 2/17 (11.8%)   | 1.07 (0.27–4.28)       | 1.79 (0.43–7.45)        | **17.69 (2.88–108.8)**      | **1.66 (0.37–7.44)**        |
| Stroke                     | No 35/471 (7.4%)   | 0.50 (0.36–0.70)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 7/28 (25.0%)   | 1.70 (0.81–3.56)       | **3.38 (1.49–7.68)**   | **7.05 (1.91–26.07)**       | **3.52 (1.46–8.45)**        |
| Acute renal disease        | No 39/493 (7.9%)   | 0.53 (0.39–0.73)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 3/5 (60.0%)    | 10.73 (3.46–33.2)      | **11.78 (3.60–38.53)** | **16.89 (3.10–91.96)**      | **13.73 (3.81–49.47)**      |
| Chronic renal disease      | No 26/405 (6.4%)   | 0.43 (0.29–0.63)       | 1 (Reference)           | 1 (Reference)               | 1 (Reference)               |
|                            | Yes 16/194 (10.0%) | 1.24 (0.76–2.02)       | **2.91 (1.55–5.49)**   | **2.69 (0.77–9.45)**        | **2.73 (1.26–5.93)**        |

Mortality rates were calculated per 100 persons-day of follow-up.

* The model was adjusted for gender, age, place of origin, education level, time of disease, hospital admission, treatment, and glycemic control.

** The imputed model was adjusted for the same variables listed above; missing values of glycemic control and time of disease were imputed.

Although results of imputed models were consistent, values of HR were markedly attenuated (Table 4).

4. Discussion

4.1. Main Findings. In the present study, respiratory infections, stroke, and acute renal failure were positively associated with dying during hospitalization after controlling for several potential confounders. Conversely, a hospital admission with the diagnosis of diabetic foot was negatively associated with mortality. In addition, an increasing number of morbidities were associated with greater risk of death.

4.2. Inhospital Mortality and Associated Risk Factors. There are few prospective studies evaluating diagnosis at the moment of hospital admission as potential risk factors for inhospital mortality among T2D patients. One of the most recent studies, conducted in UK [12], identified that hospital-admitted T2D patients had 6.4% greater risk of dying over two years than what would be expected compared to similar patients without diabetes. In addition, according to that study, the risk of death varied according to reason of admission: cardiac disease or urinary tract disease showed the highest number of additional deaths. However, most of the inhospital mortality studies are retrospective in nature. A 7-year cohort study using the General Practice Research Database in UK...
reported an all-cause mortality estimate of 9.8% among T2D patients and 3.0% of cardiovascular deaths [13]. Additionally, a previous study showed that mortality patterns changed according to race; thus, blacks were at lower risk of dying from ischemic heart disease or respiratory disorders than whites but at higher risk due to renal failure, heart failure, and cancer [14]. On the other hand, two studies conducted in India reported divergent results: one of them showed a mortality rate of 7.1% and infections were the leading cause of death, followed by chronic renal failure, coronary artery disease, and cerebrovascular disease [15], whereas a recent one reported vascular disease as the leading cause of death [4].

Two previous studies performed several years ago in Peru deserve attention. One of them reported that more than half (52%) of the hospital admissions in T2D patients were due to infections, mainly focused on soft tissues and urinary and respiratory tract, followed by chronic renal failure (24%) and heart failure (7%) [16]. The other study reported that 7.6% of patients admitted to hospitalization died and infections were the leading cause of inhospital mortality [5]. Comparing with our results, inhospital mortality was almost the same, but causes of death might have changed over time.

Although infections still increase inhospital mortality among T2D patients, other causes, especially stroke, and acute renal failure, are also potential risk factors for inhospital mortality. As countries are at different stages of nutrition and epidemiological transition, it is possible that causes of death can vary according to the setting evaluated. Then, there is a need to understand characteristics associated with the risk of death in each country and even within it. For example, about 70% of patients must pay to receive health care in public hospitals, even when most of the T2D patients are covered by the national health insurance (SIS in Spanish). This might, then, imply a new challenge in the health care system as appropriate strategies are needed in order to prevent and reduce inhospital mortality.

The negative association between diabetic foot infection and mortality merits some comments. As diabetic foot infection was one of the main causes of hospital admission in Peru [16], standardized clinical guidelines [17] have been adapted to adequately treat this complication in our context; as a result, cases with diabetic foot are treated aggressively. Moreover, amputation can help to reduce or delay death in this group [18]. A previous study from Iran reported that 5.6% of hospital-admitted T2D cases with diabetic foot infection died due mainly to sepsis [19]. In our study, 4.5% of cases with diabetic foot infection died during hospitalization, most of them (72.1%) with grade 3, 4, or 5 in the Wagner classification of diabetic foot [20].

4.3. Additional Findings. Only a quarter of hospital-admitted patients met recommended HbA1c levels, carrying out particular challenges especially in resource-constrained settings including rate of complications, number of hospitalizations, and out-of-pocket payments to cover health care [21]. Adequate glycemic control reduces the risk of developing complications such as stroke, cardiovascular events, amputation, and chronic renal disease [22]. However, several studies in different settings have reported suboptimal glycemic control rates among T2D patients [23–25]. Moreover, a decrease in adequate glycemic control rates has been also observed during past years in some locations [26]. In addition, two-thirds of patients reported not receiving antidiabetic treatment before hospitalization, which together with low glycemic control could explain the occurrence of complications and the need for hospitalization. On the other hand, during hospitalization, 66% of the patients received any form of insulin therapy; whereas only 16% received oral antidiabetic treatment (data not shown).

4.4. Limitations and Strengths. Strength of this study included its prospective nature, the standardized assessment conducted by one health care staff to verify and confirm the diagnosis and the reason of hospitalization, and the use of one of the main referral hospitals in Lima to perform the study. This study, however, has some limitations. First, the high proportion of missing values in the case of HbA1c and time of disease variables could have affected our results. Although other studies have had the same problem [27, 28], our results were consistent using different techniques, including multiple imputation models. Second, some variables used in previous studies [4, 29] were not considered in our regression models, including socioeconomic status, race, the number of previous hospital admissions, history of cancer, fasting glucose assessment, depression as well as other mental illnesses, and potassium and sodium levels [3, 4, 12, 13]. Finally, some selection bias may arise due to the selection of a referral hospital instead of primary care facilities or T2D patients from the general population. Therefore, our results, although important, cannot be inferable to different health
and social realities. However, we expect that results can be applicable to similar contexts.

5. Conclusions

Respiratory infections, stroke, and acute renal disease, as diagnosis of hospital admission, increased the risk of inhospital mortality among T2D patients, whereas the presence of diabetic foot was a protective factor. In addition, an increasing number of conditions were also associated with greater risk of mortality. Results of this study confirm that infections are not the only potential cause of inhospital mortality in a developing country and certain causes of hospital admission require a more aggressive and standardized management in order to decrease mortality among T2D patients.

Novelty Statement

There are not enough prospective studies assessing risk factors of inhospital mortality in T2D patients, especially in low- and middle-income countries (LMIC), such as Peru. Different regression models were generated to evaluate the association between reason of hospitalization and inhospital mortality. We found that infections are not the only cause of inhospital mortality, as the literature used to report, but also stroke and acute renal disease increased the risk of inhospital mortality in a transitioning setting.

Conflict of Interests

No one of the authors of this paper has reported a conflict of interests.

Acknowledgments

The authors would like to thank Giovanna Rodríguez, M.D., for her advisory during the study; third-year Endocrinology residents, Nancy Gonzales, M.D., and Anabella Pilar Alegria, M.D., for their active participation in collecting data; and Giancarlo Sal y Rosas, Ph.D., for his help and suggestions in statistical analysis. Antonio Bernabe-Ortiz is funded by a Wellcome Trust Research Training Fellowship in Public Health and Tropical Medicine (103994/Z/14/Z).

References

[1] International Diabetes Federation, *IDF Diabetes Atlas*, IDF, Brussels, Belgium, 6th edition, 2013.
[2] International Diabetes Federation, *International Diabetes Atlas*, International Diabetes Federation, Brussels, Belgium, 5th edition, 2011.
[3] S. E. Moss, R. Klein, and B. E. K. Klein, "Cause-specific mortality in a population-based study of diabetes," *American Journal of Public Health*, vol. 81, no. 9, pp. 1158–1162, 1991.
[4] S. K. Vasan, A. E. I. Pittard, J. Abraham, P. Samuel, M. S. Seshadri, and N. Thomas, "Cause-specific mortality in diabetes: retrospective hospital based data from south India," *Journal of Diabetes*, vol. 4, no. 1, pp. 47–54, 2012.
[5] J. Villena, I. Burga, S. Corigliano, and J. Valdivia, "Morbidity and mortality from non-insulin dependent diabetes mellitus in the Hospital Nacional Cayetano Heredia, 1985–1995 (abstract)," *Revista Peruana de Medicina*, vol. 68, article 64, 1996.
[6] Ministerio de Salud, *Hospital Loayza: Estadística de Atención*, MINSA, Lima, Peru, 2014.
[7] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, "Report of the expert committee on the diagnosis and classification of diabetes mellitus," *Diabetes Care*, vol. 26, supplement 1, pp. S5–S20, 2003.
[8] P. Royston, "Multiple imputation of missing values," *The Stata Journal*, vol. 4, no. 3, pp. 227–241, 2004.
[9] P. Royston, J. B. Carlin, and I. R. White, "Multiple imputation of missing values: new features for mim," *Stata Journal*, vol. 9, no. 2, pp. 252–264, 2009.
[10] I. R. White, P. Royston, and A. M. Wood, "Multiple imputation using chained equations: issues and guidance for practice," *Statistics in Medicine*, vol. 30, no. 4, pp. 377–399, 2011.
[11] Y. He, "Missing data analysis using multiple imputation: getting to the heart of the matter," *Circulation: Cardiovascular Quality and Outcomes*, vol. 3, no. 1, pp. 98–105, 2010.
[12] N. Holman, R. Hillson, and R. J. Young, "Excess mortality during hospital stays among patients with recorded diabetes compared with those without diabetes," *Diabetic Medicine*, vol. 30, no. 12, pp. 1393–1402, 2013.
[13] K. S. Taylor, C. J. Henehan, A. J. Farmer et al., "All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database," *Diabetes Care*, vol. 36, no. 8, pp. 2366–2371, 2013.
[14] B. N. Conway, M. E. May, A. Fischl, J. Frisbee, X. Han, and W. J. Blot, "Cause-specific mortality by race in low-income Black and White people with Type 2 diabetes," *Diabetic Medicine*, vol. 32, no. 1, pp. 33–41, 2014.
[15] A. H. Zargar, A. I. Wani, S. R. Masoodi et al., "Causes of mortality in diabetes mellitus: data from a tertiary teaching hospital in India," *Postgraduate Medical Journal*, vol. 85, no. 1003, pp. 227–232, 2009.
[16] G. G. Tapia, J. L. Chirinos, and L. M. Tapia, "Sociodemographic and clinical characteristics of type 2 diabetes patients with community-acquired infections admitted in medicine services of the Hospital Nacional Cayetano Heredia," *Revista Medica Herediana*, vol. 11, pp. 89–96, 2000.
[17] R. G. Frykberg, T. Zgonis, D. G. Armstrong et al., "Diabetic foot disorders. A clinical practice guideline (2006 revision)," *Journal of Foot and Ankle Surgery*, vol. 45, no. 5, pp. S1–S66, 2006.
[18] S. Morbach, H. Furchert, U. Gröblinghoff et al., "Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade," *Diabetes Care*, vol. 35, no. 10, pp. 2021–2027, 2012.
[19] A. Hadadi, H. Omdeh Ghiasi, M. Hajabdolbaghi, M. Zan-dekarimi, and R. Hamidian, "Diabetic foot: infections and outcomes in Iranian admitted patients," *Jundishapur Journal of Microbiology*, vol. 7, no. 7, Article ID e10680, 2014.
[20] D. G. Armstrong and L. A. Lavery, "Diabetic foot ulcers: prevention, diagnosis and classification," *American Family Physician*, vol. 57, no. 6, pp. 1325–1332, 1998.
[21] American Diabetes Association, "Standards of medical care in diabetes—2009," *Diabetes Care*, vol. 32, supplement 1, pp. S13–S61, 2008.
[22] World Health Organization, *10 Facts about Diabetes*, WHO, Geneva, Switzerland, 2014.

[23] D. Hu, P. Fu, J. Xie et al., "Increasing prevalence and low awareness, treatment and control of diabetes mellitus among Chinese adults: the InterASIA study," *Diabetes Research and Clinical Practice*, vol. 81, no. 2, pp. 250–257, 2008.

[24] M.-Z. Li, L. Su, B.-Y. Liang et al., "Trends in prevalence, awareness, treatment, and control of diabetes mellitus in mainland China from 1979 to 2012," *International Journal of Endocrinology*, vol. 2013, Article ID 753150, 14 pages, 2013.

[25] M. McDonald, R. P. Hertz, A. N. Unger, and M. B. Lustik, "Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older," *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 64, no. 2, pp. 256–263, 2009.

[26] C. E. Koro, S. J. Bowlin, N. Bourgeois, and D. O. Fedder, "Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report," *Diabetes Care*, vol. 27, no. 1, pp. 17–20, 2004.

[27] F. J. Gomez-Perez, C. A. Aguilar-Salinas, P. Almeda-Valdes, D. Cuevas-Ramos, I. Lerman Garber, and J. A. Rull, "HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article," *Archives of Medical Research*, vol. 41, no. 4, pp. 302–308, 2010.

[28] H. Siddique, M. M. Alam, A. W. Safi, W. B. Leong, K. Crowley, and A. A. Tahran, "In-patient diabetes care: the impact of diabetes outreach team on long-term glycaemic control," *International Journal of Clinical Practice*, vol. 68, no. 11, pp. 1333–1337, 2014.

[29] S. R. K. Seshasai, S. Kaptoge, A. Thompson et al., "Diabetes mellitus, fasting glucose, and risk of cause-specific death," *The New England Journal of Medicine*, vol. 364, no. 9, pp. 829–841, 2011.

[30] R. L. Mehta, J. A. Kellum, S. V. Shah et al., "Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury," *Critical Care*, vol. 11, no. 2, article R31, 2007.

[31] D. Fliser, M. Laville, A. Covic et al., "A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy," *Nephrology Dialysis Transplantation*, vol. 27, no. 12, Article ID gfs375, pp. 4263–4272, 2012.

[32] G. Eknoyan, N. Lameire, K. U. Eckardt et al., "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease," *Kidney International*, vol. 3, pp. 5–14, 2013.